In the Clinical/Scientific Note “Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort” by Caronna et al., 1 there were errors in the affiliations of 29 of 96 authors. The article has been replaced with a corrected version. The publisher and authors regret the errors.
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort / Caronna, E., Mas-de-les-Valls, R., Egeo, G., Vazquez, M.M., Nieves-Castellanos, C., Portocarrero, L., Vaghi, G., Rodriguez-Montolio, J., Jaimes, A., Munoz-Vendrell, A., Oliveira, R., Polanco, M., Osorio, Y.G., Canales, J., Ornello, R., Thunstedt, C., Fernandez-Lazaro, I., Husoy, A., Sanchez-Soblechero, A., Vicente, B.N., et al.. - In: NEUROLOGY. - ISSN 0028-3878. - 106:12(2026). [10.1212/WNL.0000000000214945]
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort
Caronna E.;Torelli P.Membro del Collaboration Group
;Albanese M.;Sacco S.;
2026-01-01
Abstract
In the Clinical/Scientific Note “Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort” by Caronna et al., 1 there were errors in the affiliations of 29 of 96 authors. The article has been replaced with a corrected version. The publisher and authors regret the errors.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
